Paper42895897PubMed
Sorting nexin 10 promotes triple-negative breast cancer progression through modulating cholesterol biosynthesis via stabilizing SREBP2.
Guo Y and 8 others. Cancer Biol Ther, 2026.
Cite this record
ConductScience Library. Sorting nexin 10 promotes triple-negative breast cancer progression through modulating cholesterol biosynthesis via stabilizing SREBP2. Papers, record 42895897. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42895897
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Sorting nexin 10 promotes triple-negative breast cancer progression through modulating cholesterol biosynthesis via stabilizing SREBP2.
- Journal
- Cancer Biol Ther
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-22
Source PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sorting Nexins | Major topic |
| Triple Negative Breast Neoplasms | Major topic |
| Cholesterol | Major topic |
| Sterol Regulatory Element Binding Protein 2 | Major topic |
| Humans | |
| Female | |
| Animals | |
| Mice | |
| Cell Proliferation | |
| Cell Line, Tumor | |
| Disease Progression | |
| Gene Expression Regulation, Neoplastic | |
| Mice, Nude | |
| Cell Movement | |
| Prognosis |
Source PubMed
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41342370 | Fusion of Tumor Cells with Lipid-Associated Macrophages Drives Metastatic Progression of Breast Cancer. | Cancer Res | 2026 | https://conductscience.org/library/papers/41342370 | PubMed |
| 2 | 40556739 | SNX10 in autosomal recessive osteosclerosis, osteosarcoma, rheumatoid arthritis, and osteoporosis: molecular mechanisms and therapeutic implications. | Front Cell Dev Biol | 2025 | https://conductscience.org/library/papers/40556739 | PubMed |
| 3 | 36038913 | Recent advances in therapeutic strategies for triple-negative breast cancer. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/36038913 | PubMed |
| 4 | 39603572 | Gentisic acid prevents the development of atherosclerotic lesions by inhibiting SNX10-mediated stabilization of LRP6. | Pharmacol Res | 2024 | https://conductscience.org/library/papers/39603572 | PubMed |
| 5 | 39775479 | Cholesterol Metabolism in CNS Diseases: The Potential of SREBP2 and LXR as Therapeutic Targets. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/39775479 | PubMed |
| 6 | 32517735 | Triple-negative breast cancer molecular subtyping and treatment progress. | Breast Cancer Res | 2020 | https://conductscience.org/library/papers/32517735 | PubMed |
| 7 | 29355659 | Sorting nexin 10 acts as a tumor suppressor in tumorigenesis and progression of colorectal cancer through regulating chaperone mediated autophagy degradation of p21Cip1/WAF1. | Cancer Lett | 2018 | https://conductscience.org/library/papers/29355659 | PubMed |
| 8 | 34116656 | SNX10 and PTGDS are associated with the progression and prognosis of cervical squamous cell carcinoma. | BMC Cancer | 2021 | https://conductscience.org/library/papers/34116656 | PubMed |
| 9 | 40927753 | PRMT1-Mediated PARP1 Methylation Drives Lung Metastasis and Chemoresistance via P65 Activation in Triple-Negative Breast Cancer. | Research (Wash D C) | 2025 | https://conductscience.org/library/papers/40927753 | PubMed |
| 10 | 40228127 | SNX10 deficiency impairs sensitivity to anti-HER2 antibody-drug conjugates via altering HER2 trafficking in HER2-positive breast cancer. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/40228127 | PubMed |
| 11 | 39805872 | Increased SOAT2 expression in aged regulatory T cells is associated with altered cholesterol metabolism and reduced anti-tumor immunity. | Nat Commun | 2025 | https://conductscience.org/library/papers/39805872 | PubMed |
| 12 | 39095084 | SNX10 regulates osteoclastogenic cell fusion and osteoclast size in mice. | J Bone Miner Res | 2024 | https://conductscience.org/library/papers/39095084 | PubMed |
| 13 | 33945792 | Lipid metabolism in cancer: New perspectives and emerging mechanisms. | Dev Cell | 2021 | https://conductscience.org/library/papers/33945792 | PubMed |
| 14 | 39367898 | Inhibiting SNX10 induces autophagy to suppress invasion and EMT and inhibits the PI3K/AKT pathway in cervical cancer. | Clin Transl Oncol | 2025 | https://conductscience.org/library/papers/39367898 | PubMed |
| 15 | 30487700 | Prognostic value of sorting nexin 10 weak expression in stomach adenocarcinoma revealed by weighted gene co-expression network analysis. | World J Gastroenterol | 2018 | https://conductscience.org/library/papers/30487700 | PubMed |
| 16 | 37253507 | Advances in systemic therapies for triple negative breast cancer. | BMJ | 2023 | https://conductscience.org/library/papers/37253507 | PubMed |
| 17 | 33241559 | The molecular structure and function of sorting nexin 10 in skeletal disorders, cancers, and other pathological conditions. | J Cell Physiol | 2021 | https://conductscience.org/library/papers/33241559 | PubMed |
| 18 | 31848472 | Mechanisms and regulation of cholesterol homeostasis. | Nat Rev Mol Cell Biol | 2020 | https://conductscience.org/library/papers/31848472 | PubMed |
| 19 | 39817679 | Cancer statistics, 2025. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/39817679 | PubMed |
| 20 | 38420162 | Multi-omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple-negative breast cancer. | MedComm (2020) | 2024 | https://conductscience.org/library/papers/38420162 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42895897
GET https://conductscience.org/api/papers/v1/42895897/references?page=2